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Objectives The purpose of this study was to determine patient compliance and effectiveness of antiarrhythmic treatment by
the wearable cardioverter-defibrillator (WCD).
Background Effectiveness of the WCD for prevention of sudden death is dependent on event type, patient compliance, and
appropriate management of ventricular tachycardia/ventricular fibrillation (VT/VF).
Methods Compliance and events were recorded in a nationwide registry of post-market release WCDs. Survival, using the
Social Security Death Index, was compared with survival in implantable cardioverter-defibrillator (ICD) patients.
Results Of 3,569 patients wearing the WCD (age 59.3  14.7 years, duration 52.6  69.9 days), daily use was 19.9 
4.7 h (90% of the day) in 52% of patients. More days of use correlated with higher daily use (p  0.001).
Eighty sustained VT/VF events occurred in 59 patients (1.7%). First-shock success was 76 of 76 (100%) for un-
conscious VT/VF and 79 of 80 (99%) for all VT/VF. Eight patients died after successful conversion of uncon-
scious VT/VF (89.5% survival of VT/VF events). Asystole occurred in 23 (17 died), pulseless electrical activity in
2, and respiratory arrest in 1 (3 died), representing 24.5% of sudden cardiac arrests. During WCD use, 3,541 of
3,569 patients (99.2%) survived overall. Survival occurred in 72 of 80 (90%) VT/VF events and 78 of 106
(73.6%) for all events. Long-term mortality was not significantly different from first ICD implant patients but
highest among patients with traditional ICD indications.
Conclusions Compliance was satisfactory with 90% wear time in 50% of patients and low sudden death mortality during
use. Survival was comparable to that of ICD patients. However, asystole was an important cause of mortality in
sudden cardiac arrest events. (J Am Coll Cardiol 2010;56:194–203) © 2010 by the American College of Cardi-
ology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.04.016Several studies have demonstrated implantable cardioverter-
defibrillator (ICD) devices to be effective in primary and
secondary sudden cardiac death (SCD) prevention in high-
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indications for ICD use.
However, despite identification of risk factors indicating
a high risk of SCD, ICD implantation is commonly
deferred in a variety of clinical situations. Several primary
prevention studies of SCD excluded patients early after
acute myocardial infarction (MI) or coronary revasculariza-
See page 204
tion (4,5), leading to exclusion of such patients from early
prophylactic ICD implantation. Moreover, early ICD im-
plantation 6 to 40 days after acute MI with left ventricular
ejection (LVEF) 35% has not been shown to improve
early overall survival, despite a reduction in arrhythmic
deaths, because patients receiving ICD shocks are at high
risk of nonarrhythmic deaths during this early period (6). In
Medicare patients with LVEF 35% and New York Heart
Association functional class II or III heart failure, ICD
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diomyopathy within 3 months of diagnosis and for ischemic
cardiomyopathy within 40 days of acute MI or 3 months of
revascularization. Nevertheless, SCD risk may be highest early
after diagnosis or MI, as the VALIANT (Valsartan in Acute
Myocardial Infarction) study demonstrated by reporting that
SCD risk appears highest in the first 30 days after MI in
patients with left ventricular dysfunction or heart failure (7).
ICD implantation may also need to be deferred in patients
with surgical contraindications, ventricular thrombi, treatable
comorbidities, vascular obstructions, infections, or awaiting
clearance of infection for reimplantation after extraction.
Once discharged from the hospital, these patients gener-
ally rely on emergency medical services for resuscitation
should they have a sudden cardiac arrest (SCA). Additional
protection has been proposed through means that include
bridging with an automatic external defibrillator, antiar-
rhythmic drugs, or a wearable cardioverter-defibrillator
(WCD). However, the automatic external defibrillator is
limited by requiring a bystander to apply the defibrillator,
and antiarrhythmic drugs, including amiodarone, may not
be better than placebo in the prevention of SCD (1,2).
The WCD is an external device capable of automatic
entricular tachycardia (VT)/ventricular fibrillation (VF)
etection and defibrillation. It has been shown to improve
CA survival over reliance on emergency medical services
8), but the efficacy of the WCD in the prevention of
rrhythmic SCD would seem to be highly dependent on
atient compliance as well as appropriate detection and
reatment of VT/VF. We sought to determine the efficacy
f the WCD in the detection and treatment of VT/VF, to
ssess compliance of patients in wearing the device, and to
ompare the long-term survival of patients who wore the
CD compared with a population of patients who under-
ent ICD implantation.
ethods
ll patients issued a WCD after market release in the U.S.
re entered into a database maintained by the manufacturer
ZOLL Cardiac Management Solutions, Pittsburgh, Penn-
ylvania) for regulatory, reimbursement, and tracking pur-
oses. The database contains indications, baseline demo-
raphics (age and sex), compliance, and events. All patients
igned consent to use their data for quality monitoring,
ealth care operation activities, and/or research. Patients in
he U.S. who wore the WCD from August 2002 through
ecember 2006 were included in this study. Survival of
hese patients was compared with that of a population of
atients who underwent first ICD implantation at the
leveland Clinic. Mortality outcomes of WCD patients
ith Social Security numbers were determined from the
ocial Security Death Index (SSDI) and de-identified
urvival data compared with SSDI-determined survival data
n an ICD population studied under a retrospective medicalecords review protocol approved
y the Cleveland Clinic Institu-
ional Review Board.
CD description. The WCD
s composed of 4 dry, nonadhe-
ive capacitive electrodes for
onitoring 2 surface electrocar-
iogram leads, 3 nonadhesive de-
brillation electrodes incorpo-
ated into a chest strap assembly,
nd a 1.7-lbs defibrillator unit
arried on a waist belt. The mon-
toring electrodes are positioned
ircumferentially around the
hest and held in place by about
.5 lbs of tension from an elastic
elt. The defibrillation electrodes
re positioned for apex-posterior
efibrillation. If an arrhythmia is
etected, an escalating alarm se-
uence starts, including a vibra-
ion against the skin, audible
ones, and a voice cautioning bystanders of an impending
hock. Patients are trained to hold a pair of response buttons
uring these alarms. Responding acts as a test of conscious-
ess; if no response occurs, the device charges, extrudes gel
rom the defibrillation electrodes, and delivers up to 5
iphasic shocks of pre-programmable energy levels with
aximum output of 150 J. The WCD records time/date
tamps for device on/off switching, monitor connection to
he electrodes, and electrode-to-skin contact.
efinitions. For this study, compliance was defined as the
ime during a day that a WCD user had the device on, the
elt connected, and at least one electrocardiogram lead
ontacting the skin. Days were determined as any day with
t least some WCD use. During the compliance calculation,
day was subtracted from the total number of days to
ompensate for the expected partial use on the first and last
ays.
Electrocardiogram and defibrillation electrode contact was
etermined by microampere AC signals similar to conven-
ional monitoring systems. The device also recorded electro-
ardiogram data for rhythms greater than a pre-programmed
ate threshold that did not match a baseline template and
efined such arrhythmias as ventricular arrhythmias. A buffer
n the monitoring software captured 30 s of electrocardiogram
ignal before the determination of VT/VF. Treatment event
utcomes were determined through phone contact with pa-
ients or medical personnel. In addition to recording potential
T/VF, asystole recordings occurred when the ventricular rate
ropped below 20 beats/min (minimum detected QRS height
00V). The buffer incorporated into the monitoring software
stored 5 min of an electrocardiogram before the asystole
determination.
For the purposes of this study, all potentially lethal
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
SCA  sudden cardiac
arrest
SCD  sudden cardiac
death
SSDI  Social Security
Death Index
VF  ventricular fibrillation
VT  ventricular
tachycardia
WCD  wearable
cardioverter-defibrillatorarrhythmias (sustained VT/VF or asystole) occurring within
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Wearable Cardioverter-Defibrillator Outcomes July 13, 2010:194–20324 h were considered a single SCA event. In addition to
reviewing electrocardiogram records stored by the WCD,
patient call reports were reviewed for reports of deaths while
wearing a WCD. All such reports were explored to further
isolate the cause of death, if possible. A ZOLL physician
determined WCD shocks to be appropriate if they occurred
on sustained VT/VF and inappropriate if not. Inappropriate
shocks were further analyzed for inappropriate detection
cause from electrocardiogram recordings and lack of re-
sponse button use from patient call reports. Two-lead
electrocardiograms from all shocks and baseline tracings
were reviewed by 2 authors (S.J.S., E.Z.) and differences
adjudicated by consensus with the first author (M.K.C.).
Although the WCD did not have pacing capability in this
version, it recorded asystole events and broadcast “device
disabled, call ambulance” to enlist bystander help once
asystole was detected.
Indications for WCD use. Indications for WCD were
based on Medicare Durable Medical Equipment Regional
Carrier local coverage policies for use. Because no coverage
policy was in effect before January 2005, categories were
added for patients who did not fit into the coverage policies.
Indications included the following:
1. ICD explantation with delayed reimplantation (e.g.,
extended antibiotic therapy for infections)
2. Delays in ICD implantation (e.g., comorbidities) after a
VF or sustained VT event
3. Delays in ICD implantation for genetic arrhythmogenic
syndromes or congenital heart disease
4. Before ICD evaluation after MI with LVEF 35%
5. Before ICD evaluation after revascularization with
LVEF 35% and past MI
. Before ICD evaluation after diagnosis with nonischemic
cardiomyopathy and LVEF 35%
. Unspecified cardiomyopathy with LVEF 35%
. MI with an LVEF 35% or unspecified
. Other temporary or fluctuating SCD risk conditions
(e.g., waiting for cardiac transplant)
f 1 category was specified, patients were grouped accord-
ng to the following hierarchy: ICD explant  VF or
ustained VT event  genetic or congenital SCA risk 
onischemic cardiomyopathy with low LVEF  coronary
rtery bypass graft (CABG) with low LVEF and previous
I  MI with low LVEF  MI with high or unknown
VEF  unknown low LVEF  other.
Survival outcomes were also analyzed by WCD indica-
ions, grouped by whether patients met traditional or
ontraditional ICD indications. Traditional ICD indica-
ions included patients who underwent ICD explantation,
ad VT/VF while awaiting ICD implantation, genetic
redisposition to SCD, or LVEF 35% with unspecified
ardiomyopathy. Nontraditional ICD indications included
ecent MI, post-CABG, recent nonischemic cardiomyopa-
hy, and miscellaneous or unknown indications.CD population. Patients undergoing a first ICD implan-
ation at the Cleveland Clinic between August 1996 and
ay 2004 were identified from a prospectively collected
atabase in the Cleveland Clinic Electrophysiology Labo-
atory. Mortality was determined by the SSDI.
tatistical analysis. Data are reported as mean  SD
nless otherwise stated. Data were compared using Student
tests for continuous variables and chi-square tests for
iscrete variables. Kaplan-Meier survival analysis was per-
ormed for the WCD and ICD groups. Cox proportional
azards modeling was performed for adjusted survival anal-
ses. Data were considered statistically significant at a
-sided p value 0.05. All analyses were conducted using
AS version 9.1.3 (SAS Institute, Cary, North Carolina).
esults
atient population. A total of 3,569 patients wore the
CD for at least 1 day. Baseline demographics were
vailable for 2,731 patients (Table 1). Mean age was 59.3 
4.7 years (range 12 to 93 years, n  2,723). Indications
ere unknown in 838 (23%) due to missing links between
linical and reimbursement datasets, primarily during early
ommercial use. Use totaled 143,643 patient-days. Mean
uration of use was 52.6 69.9 days (range 1 to 1,590 days)
Fig. 1A).
ompliance. Daily use for each patient (available in 2,208
atients) was calculated by dividing the total hours worn by
he number of days worn minus 1, to adjust for partial use
n the first and last days worn. Median daily use was 21.7 h
91% of time available). Mean daily use was 19.9  4.7 h,
ange 0.4 to 25.9 h (24 h possible due to the methodology
sed to adjust for partial days at the beginning and end of
se, although internal clocking errors cannot be completely
xcluded). Daily use was 90% in 52% of patients and
80% in 71% of patients. Of 2,169 patients with recorded
ata, 307 (14.2%) stopped wearing the WCD prematurely
Patient CharacteristicsTable 1 Patient Characteristics
Sex, male 2,000/2,720 (74%)
Age, yrs 59.3 14.6
Indications 2,731
ICD explants 638 (23.4%)
VT/VF before ICD implantation 439 (16.1%)
Genetic predisposition to SCD 12 (0.4%)
LVEF 35%
Recent MI 341 (12.5%)
Post-CABG 243 (8.9%)
Nonischemic cardiomyopathy 546 (20.0%)
Unspecified cardiomyopathy 222 (8.1%)
LVEF 35%, recent MI 104 (3.8%)
Miscellaneous or unknown 186 (6.8%)
Duration of monitoring, days 52.6 69.9 (1–1,590)
CABG coronary artery bypass graft surgery; ICD implantable cardioverter-defibrillator; LVEF
left ventricular ejection fraction; MI  myocardial infarction; SCD  sudden cardiac death;
VT/VF  ventricular tachycardia/ventricular fibrillation.
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July 13, 2010:194–203 Wearable Cardioverter-Defibrillator Outcomesbecause of comfort issues or adverse reactions, primarily the
size and weight of the monitor.
Longer duration of monitoring correlated with higher com-
pliance rates (Fig. 1B). Patients using the device 60 days (n
 599) averaged 20.8 3.7 h per day, significantly more than
Figure 1 Actual WCD Use
Duration of monitoring. (A) Distribution of patients by duration of wearable car-
dioverter-defibrillator (WCD) use. (B) Daily hours of use by overall duration of
WCD use.
Figure 2 Events While Wearing the WCD
ECG  electrocardiogram; PM  pacemaker; VT/VF  ventricular tachycardia/venall other groups except those using it between 45 and 60 days
(p 0.05). Patients using it15 days (n 160) averaged 17.2
 5.9 h, significantly less than all other groups (p  0.001).
Arrhythmia events, treatment efficacy, and mortality
during WCD use. The WCD was designed to treat
sustained VT/VF and to record sustained VT/VF and
asystole. Thus, most SCA events were expected to have an
associated electrocardiogram record. Events are shown in
Figure 2 and Table 2. There were 3 reports of deaths while
a WCD was worn that did not have an associated WCD
electrocardiogram recording. Two were from pulseless elec-
trical activity confirmed by hospital telemetry recordings,
and 1 was due to a respiratory arrest, documented by a
physician present at the event (a prison medical ward),
although telemetry recordings were not documented to
determine the presence or absence of an arrhythmia. The
number of patients who died not wearing the WCD was not
recorded in the database but determined using the SSDI.
During the time that the WCD was worn, 80 sustained
VT/VF events occurred in 59 patients (1.7% of the total
number of patients). Four patients reported being conscious
during the shock. First-shock success was 76 of 76 (100%)
among unconscious patients and 79 of 80 (99%) for all
patients. The single failure to halt VT/VF on the first
attempt occurred when a conscious patient with sustained
VT allowed himself to be shocked after 10 min of using the
WCD response buttons to delay the shock. He was later
shocked while conscious during his ambulance ride to the
hospital (2 shocks, 100 and 200 J) and in the emergency
department (2 shocks, 50 and 200 J). All shocks were
ineffective, although pharmacologic therapy restored a nor-
mal rhythm within hours. This patient was using a WCD
after ICD explantation due to device infection; the original
indication for ICD implantation is unknown. Eight patients
died after successful conversion of unconscious VT/VF;
survival occurred in 89.5% of events. Four patients died due
to recurrent arrhythmias after initially recovering conscious-
ness and the arrival of professional medical care (1 ambu-
r fibrillation; other abbreviation as in Figure 1.tricula
t
w
o
t
i
S
E
i
t
t
w
c

d
S
t
g
I
(
m
t
c
l
I
c
w
g
a
t
s
I
g
t
i
ck. Oth
rter-de
198 Chung et al. JACC Vol. 56, No. 3, 2010
Wearable Cardioverter-Defibrillator Outcomes July 13, 2010:194–203lance death, 1 emergency department death, 2 telemetry
deaths). One patient’s spouse prevented a second WCD
shock for a recurrent ventricular tachyarrhythmia minutes
after a first successful shock. Two patients with recurrent
arrhythmias were prevented or delayed from getting a
second shock due to electrocardiogram signal disruption
believed secondary to falling and wedging their bodies in an
unfavorable position for proper electrode contact. The last
patient had a unipolar pacemaker that paced during an
episode of VF, and the large pacing artifact prevented
WCD arrhythmia detection from proceeding to shock (14).
NONTACHYARRHYTHMIA EVENTS. There were 23 asystole
events recorded (17 deaths) and 3 pulseless electrical activity
or respiratory arrests (3 deaths) while wearing the WCD, all
confirmed by medical personnel present at the time. These
non-VT/VF events accounted for 26 of 106 (24.5%) SCAs.
One patient who was treated for VT/VF several times died
4 days after the last treatment with asystole as the presenting
arrhythmia. Two treatments for VT/VF shocked the
rhythm into asystole (no cardiac signal for at least 15 s),
but both survived with return of rhythm. Inappropriate
shocks (not occurring on sustained VT or VF) occurred
in 67 of 3,569 (1.9%) patients during 4,788 months of use
(1.4% per month). Inappropriate shocks are a combina-
tion of sustained inappropriate detections by the WCD
and failure to use the response buttons by the patient.
Reasons for inappropriate detection were (multiple rea-
sons possible during a detection): electrocardiographic
signal loss, 4.4%; multicounting on normal cardiac signal,
4.4%; signal artifact, 67.6%; supraventricular tachycardia,
26.5%; and nonsustained VT, 5.9%. Patient-reported rea-
sons for failure to use the response buttons were (1 reason
recorded per episode): inconsistent or unconcerned (32.4%),
physically or mentally unable to respond (11.8%), sleeping
(26.5%), did not remember why (10.3%), did not remember
training (10.3%), mental or physical obstacle at the time
Events by IndicationTable 2 Events by Indication
Indications for WCD Use n (%)
Duration of Use
(Days)
Patie
VT/
We
Traditional ICD indications
ICD explants 638 (23.4%) 56.1 77.7
VT/VF before ICD implant 439 (16.1%) 49.6 71.1
Genetic predisposition to SCD 12 (0.4%) 56.2 75.6
LVEF 35%, cardiomyopathy 222 (8.1%) 56.6 117.4
Nontraditional ICD indications
LVEF 35%
Recent MI 341 (12.5%) 47.8 38.9
Post-CABG 243 (8.9%) 46.5 44.0
Recent NICM 546 (20.0%) 56.5 59.1
LVEF 35%, recent MI 104 (3.8%) 50.0 48.8
Miscellaneous or unknown 186 (6.8%) 49.3 73.1
*To be counted as a separate event, the VT/VF shock had to occur at least 24 h from the last sho
NICM  nonischemic cardiomyopathy; SCA  sudden cardiac arrest; WCD  wearable cardiove(4.4%), and did not hear alarms (4.4%). rOVERALL ACUTE SURVIVAL. Overall acute survival during
he time of WCD use was 99.2% (3,541 of 3,569 patients)
ith 0.78% sudden death mortality over a mean usage time
f 53 days. Survival was 72 of 80 (90%) for ventricular
achyarrhythmia events and 78 of 106 (73.6%) for all events,
ncluding non-VT/VF events.
urvival and events in WCD patients by device indication.
vents in individual traditional and nontraditional ICD
ndications are shown in Table 2. Among patients with
raditional ICD indications, the WCD recorded events in
he groups with ICD explanted and a history of VT/VF
hile awaiting ICD implantation. No shocked events oc-
urred in the genetic predisposition to SCD and LVEF
35% cardiomyopathy groups, although 2 SCA events and
eaths occurred in the LVEF35% cardiomyopathy group.
hocked events occurred in all nontraditional ICD indica-
ions groups, except the recent MI with LVEF 35%
roup.
Survival by traditional compared with nontraditional
CD indications was analyzed based on SSDI mortality data
n 2,147). Long-term (3-year) and short-term (3-month)
ortality was significantly worse in the group with tradi-
ional ICD indications (Fig. 3). Short-term Kaplan-Meier
urves for individual indications are shown in Figure 4, and
ong-term mortality estimates for the composite traditional
CD indications group and individual nontraditional indi-
ations groups are shown in Table 3. The highest mortality
as observed in 3 of the 4 traditional ICD indications
roups: cardiomyopathy with LVEF 35%, ICD explanted
waiting reimplantation, and VT/VF awaiting ICD implan-
ation. Similar long-term mortality was observed in patients
urviving a recent MI with LVEF 35%, a nontraditional
CD indication. Other nontraditional ICD indication
roups demonstrated lower mortality compared with tradi-
ional ICD indication groups. These nontraditional groups
ncluded LVEF 35% with recent MI, post-CABG, and
ith Shocked
ents While
the WCD*
VT/VF Deaths
While Wearing
the WCD
Non-VT/VF SCA
Events While
Wearing the WCD
Non-VT/VF SCA
Deaths While
Wearing the WCD
events) 2 9 7
vents) 1 0 0
vents) 0 0 0
vents) 0 2 2
events) 2 7 7
vents) 1 3 1
vents) 1 2 1
vents) 0 0 0
vents) 1 3 2
er SCA events included asystole and pulseless electrical activity.
fibrillator; other abbreviations as in Table 1.nts W
VF Ev
aring
33 (49
6 (9 e
0 (0 e
0 (0 e
10 (12
2 (2 e
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4 (4 eecent nonischemic cardiomyopathy.
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July 13, 2010:194–203 Wearable Cardioverter-Defibrillator OutcomesSurvival in WCD versus ICD groups. Patient character-
istics of WCD and ICD groups are shown in Table 4. Mean
age was higher in patients with ICDs compared with those
with WCDs. Kaplan-Meier survival curves for the WCD
and ICD groups (Fig. 5), including 3-year and 3-month
survival curves, show no significant survival differences
between the groups, including on Cox proportional hazards
analyses adjusting for age and sex (p  0.707). Estimated
mortality rates in the WCD and ICD groups (Table 3) were
ot significantly different.
iscussion
his study reports the U.S. outcomes with the WCD.
ndicated for temporary or changing SCA risk, the WCD
Figure 3 Short- and Long-Term Kaplan-Meier Survival Analyses
(A) Three-month cumulative mortality. (B) Long-term cumulative mortality. CI  co
Figure 1.ay be useful in situations in which ICD implantation iswarranted but deferred. Use has been limited by perceptions
that patient compliance is low. The data reported here show
compliance of at least 90% for the majority of users. Survival
was comparable to that of a population of patients with
ICDs.
In this study, 14.2% stopped wearing the WCD because
of comfort issues or adverse reactions. In a previous pub-
lished investigational study of the WCD, 68 of 289 patients
(24.5%) stopped wearing an earlier version of the WCD.
Although patients who stopped using the WCD prema-
turely complained mostly of the size and weight of the
monitor/defibrillator unit, improved compliance may have
been seen because the WCD used in this study was 40%
smaller in size and weight. In a recent study of aspirin,
CD Patients by Traditional Versus Nontraditional ICD Indications
ce interval; ICD  implantable cardioverter-defibrillator; other abbreviations as inof W
nfidenangiotensin-converting enzyme inhibitor, and beta-blocker
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Wearable Cardioverter-Defibrillator Outcomes July 13, 2010:194–203use after MI, 15% of patients stopped using all 3 medica-
tions within 30 days of hospital discharge, despite the
known survival benefits of these medications (9). The rate of
WCD discontinuation appears similar.
Figure 4 Kaplan-Meier Survival Analyses of WCD Patients by S
(A) Short-term (3 months). (B) Long-term (3 years). Traditional ICD indications inc
awaiting reimplantation, ventricular tachycardia/ventricular fibrillation (VT/VF) awai
traditional indications include recent myocardial infarction (MI) with LVEF 35%, p
recently diagnosed cardiomyopathy (CM) with LVEF 35%. Abbreviations as in Figu
Estimated 3-Year Mortality Rates in the Composite Traditional ICDComp r With Individual Non rad tional ICD Indication Gr upsTable 3 Estimate 3-Year Mortality Rates in he Composite TraCompared With Individual Nontraditional ICD Indication
n
Estimated Mortality Rate
% (95% CI)
Traditional ICD indications 1,029 26.8 (23.3–30.4)
LVEF 35%, recent MI 273 16.7 (10.1–23.3)
LVEF 35%, post-CABG 184 9.3 (5.1–13.5)
LVEF 35%, recent NICM 428 11.3 (7.0–15.5)
LVEF 35%, recent MI 87 25.6 (14.7–36.5)
Miscellaneous or unknown 104 13.2 (6.4–20.0)*Adjusted for age and sex.
CI  confidence interval; other abbreviations as in Tables 1 and 2.The shock efficacy results reported here are comparable to
those reported in investigational studies of the WCD
(8,10). In electrophysiology laboratory testing of the WCD,
100% of 20 shocks given for VF were terminated by a single
c ICD Indications
rdiomyopathy with left ventricular ejection fraction (LVEF) 35%, ICD explant
D implantation, and genetic predisposition to sudden cardiac death (SCD). Non-
ronary artery bypass graft (CABG) with LVEF 35%, recent MI with LVEF 35%,
ations Groupnal ICD Indications Group
ups
azard Ratio
(95% CI) p Value
Adjusted Hazard Ratio*
(95% CI) p Value
— — — —
9 (0.33–0.71) 0.001 0.69 (0.57–0.83) 0.001
0 (0.25–0.66) 0.001 0.72 (0.61–0.85) 0.001
4 (0.24–0.49) 0.001 0.42 (0.29–0.61) 0.001
4 (0.52–1.36) 0.48 0.94 (0.84–1.06) 0.34
4 (0.31–0.95) 0.03 0.91 (0.82–1.02) 0.11pecifi
lude ca
ting IC
ost-co
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July 13, 2010:194–203 Wearable Cardioverter-Defibrillator Outcomesshock of either 70 or 100 J (10). In 289 patients who wore the
CD, 6 of 8 (75%) defibrillation attempts were successful (8).
he 2 unsuccessful defibrillations occurred in patients who had
ncorrectly reversed the defibrillating electrodes, such that
hocks were not directed to the skin. A high first-shock
onversion rate was observed in this study by the WCD,
ndicating efficacy in conversion of VT/VF that appears com-
arable to that of ICDs. First-shock efficacy has been reported
o be 80% to 90% with ICDs (11), which deliver therapies
apidly but can also deliver shocks to conscious patients and/or
n potentially hemodynamically stable or nonsustained VT/VF
pisodes. Only 10% of appropriately treated patients reported
yncope during the AVID (Antiarrhythmics Versus Implant-
ble Defibrillators) trial. In fact, up to 40% of VF-detected
rrhythmias terminate during charging but before shock deliv-
ry (12). In contrast, WCD shocks are delivered to unrespon-
ive patients who have had at least 30 s of VT/VF and who
ave failed to respond to the alarms by pressing the response
uttons. Despite the programmed longer time to shock, shock
fficacy appears to be similar to that of shocks reported with
CDs.
During pre-market release studies, 12 deaths occurred,
ncluding 6 sudden deaths. Of these, 5 occurred in
atients not wearing the device and 1 in a patient who
eversed a defibrillation electrode (the current version
ounds an alarm when any of the defibrillation electrodes
re not touching the skin properly) (8,10). Thus, despite
se of the WCD, SCD can occur. However, as reported
ere, some SCDs may have occurred due to bystander
nterference, electrocardiogram signal disruption, or
nipolar permanent pacing inhibiting arrhythmia detec-
ion by the WCD. The latter instance emphasizes the
elative contraindication to use of the WCD with unipo-
ar pacing, as is the case with ICDs (13). Future device
mprovements, such as the already implemented detec-
ion of electrode contact and improved warnings to
ystanders, may help to reduce but is unlikely to com-
letely eliminate these issues. These results highlight the
mportance of patient education in use of the WCD, as
ell as in the critical need to promote compliance in
Patient Characteristics and EstimatedMortality Rates of WCD and ICD PatientsTable 4 Pa ient Characteristics and EstimatedMortality Rates of WCD and ICD Patients
WCD
(n  2,207)
ICD
(n  1,677) p Value
Age, yrs 59.3 14.7 62.9 12.5 0.001
Sex, male 74.6% 77.6% 0.028
Estimated mortality rates, %
3 months 3.6 4.4 0.256
6 months 6.3 7.6 0.134
1 yr 10.1 11.0 0.379
2 yrs 15.6 16.7 0.341
3 yrs 20.5 22.1 0.288
4 yrs 22.2 27.9 0.279
Abbreviations as in Tables 1 and 2.sing the WCD for the prevention of SCD. dProper instruction on use of the WCD is also important
o the avoidance of inappropriate shocks. The incidence of
nappropriate shocks was relatively low and comparable to
hat of ICDs. Inappropriate or unnecessary shocks occurred
n 6 of 289 of patients (2.1%) during 901 months of use
0.7% per month) in a previously reported study (8). In the
urrent study, inappropriate shocks occurred in 1.9% of
atients at a rate of 1.4% per month. In contrast, studies of
CDs found that 0.6% to 1.5% of inappropriate shocks
ccur per month over the first 6 months of use (14). The
bility to prevent shocks by holding the response buttons in
CD patients may have contributed to keeping a lower
nappropriate shock incidence as the sustained inappropriate
etection rate was 5 times the inappropriate shock rate. It is
nteresting to speculate from these results that this type of
hock-prevention feature might be useful for selected low-
isk arrhythmia treatment strategies in patients with ICDs.
There are few reported data on actual arrhythmic causes
f SCD. This study documented that asystole or pulseless
lectrical activity accounted for 24.5% of SCA events with
igh associated mortality rates. These data indicate the need
o incorporate pacing therapies into future WCD systems,
lthough it is unclear whether pacing would prevent deaths
n these patients.
In the analysis of events and mortality by traditional and
ontraditional ICD indications, patients with traditional
CD indications had the highest long-term mortality, rein-
orcing these groups as higher risk populations. Among
ontraditional indications groups, however, the groups with
VEF 35% and recent cardiovascular events, including
ecent MI, CABG, and a new cardiomyopathy diagnosis,
ad lower long-term mortality, perhaps reinforcing the
ppropriate deferral of ICD implantation after acute cardiac
vents and the use of the WCD while awaiting potential
mprovement in cardiac function. Paradoxically, the recent
I group with LVEF 35% demonstrated similar mortal-
ty to that of groups with traditional ICD indications. It is
ossible that there were other high-risk indicators that may
ave prompted WCD prescription, although shocked
vents did not occur in this group. Accordingly, these
ndividuals may have died of nonarrhythmic causes and may
ot have benefited from the WCD.
The long-term survival data comparing WCD and ICD
urvival are reassuring that WCD therapy may be comparable
o ICD therapy, rationalizing the use of the WCD as an
cceptable temporary alternative or a bridge to long-term ICD
mplantation. Short-term (3-month) survival estimates were
lso performed, as the mean WCD use duration was 53 days,
nd were not significantly different from those of ICD patients.
With limitations inherent to a device that is external and
nteractive, it is evident that should an ICD be indicated,
mplantation of an ICD would be clearly preferable and
erhaps significantly more efficacious than the WCD because
atient compliance is irrelevant to ICD therapy and asystolic
vents could be treated. Should ICD implantation need to be
eferred, however, a WCD may be elected, and this study
202 Chung et al. JACC Vol. 56, No. 3, 2010
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However, intensive patient and family education may be
required to reinforce the importance of compliance in achiev-
ing effective prevention of SCD with this therapy.
Study limitations. Because of the nature of the registry,
availability of demographic and daily use information was
not complete and thus could lead to potential bias in these
data. Similarly, the comparability of WCD with ICD
patients in terms of demographics and disease comorbidities
cannot be assessed.
Conclusions
The WCD was worn with 90% compliance by most pa-
tients. Sudden death mortality was 0.78% over a mean usage
time of 53 days. Survival occurred in 73.6% of events and in
90% of VT/VF events. Survival was comparable to that of ICD
Figure 5 Short- and Long-Term Kaplan-Meier Survival Analysis o
(A) 3-month cumulative mortality. (B) 3-year cumulative mortality. Abbreviations aspatients and highest in patients with traditional ICD indica-tions, rationalizing the use of the WCD as an acceptable
temporary alternative or a bridge to long-term ICD implan-
tation. However, because sudden death mortality occurred in
patients who were not wearing the WCD or who had
bystander interference, electrocardiogram signal disruption, or
unipolar pacing artifacts, patient instruction regarding proper
use of and compliance with the WCD is vital to ensuring the
efficacy of the WCD in preventing SCD. Also, asystole or
pulseless electrical activity accounted for 24.5% of SCA events
with high associated mortality rates, rationalizing the need to
incorporate pacing therapies into future WCD systems.
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